Neuropathy;PeripheralNCT06121232
Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study
A study testing Abbott® DRG / Abbott®/Medtronic® SCS in people with Neuropathy;Peripheral, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
To learn if a process called neuromodulation can help to improve pain due to CIP Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Neuropathy;Peripheral
- What is being tested?
- Abbott® DRG / Abbott®/Medtronic® SCS
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Nov 2023to 1 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Ability to understand and the willingness to sign a written informed consent document
- Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds
- Patients seen at Pain Management Center at MD Anderson Cancer Center
- Patient ages greater or equal to 18 years but less than or equal to 85 years
Who cannot join
- Patients with cognitive dysfunction
- Patient with recent history (<6 months) of drug or alcohol abuse
- Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection
- Patients with painful diabetic peripheral neuropathy or preexisting peripheral neuropathy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
M D Anderson Cancer Center
Houston, Texas, 77030
Saba Javed, M D, 713-792-9530, sjaved@mdanderson.org
Saba Javed, M D
About this study
To learn if a process called neuromodulation can help to improve pain due to CIP
Read the detailed description
Inclusion Criteria:
- Ability to understand and the willingness to sign a written informed consent document
- Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds
- Patients seen at Pain Management Center at MD Anderson Cancer Center
- Patient ages greater or equal to 18 years but less than or equal to 85 years
Exclusion Criteria:
- Patients with cognitive dysfunction
- Patient with recent history (<6 months) of drug or alcohol abuse
- Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection
- Patients with painful diabetic peripheral neuropathy or preexisting peripheral neuropathy
- Conditions
- Neuropathy;Peripheral
- Being tested
- Abbott® DRG / Abbott®/Medtronic® SCS, Control Group
- Medical subject headings
- Neuritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Abbott® DRG / Abbott®/Medtronic® SCSDevice
Participants will receive 1 of 2 neuromodulation procedures based on if participants are expected to have an MRI in the near future.
Control GroupOther
Participants will not receive any intervention
| Study group | Role | What they receive |
|---|---|---|
| Treatment Group | Experimental | Group 1 will receive neuromodulation. Receives: Device: Abbott® DRG / Abbott®/Medtronic® SCS |
| Control Group | Experimental | Group 2 will not receive neuromodulation. Receives: Other: Control Group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured: through study completion; an average of 1 year.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Nov 2023
- Study start2 Nov 2023
- Primary completion1 Jun 2028 (estimated)
- Study completion1 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neuropathy;PeripheralStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- Foundation for Anesthesia Education and Research
- Responsible party
- Sponsor
- Investigators
- Saba Javed, M D, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06121232
- Sponsor's protocol ID
- 2023-0301
- Other IDs
- NCI-2023-09269
- Status last verified
- Sep 2026
- First submitted
- 25 Oct 2023
- Last updated
- 2 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study
- ClinicalTrials.gov ID
- NCT06121232
- Acronym / sponsor ID
- 2023-0301
- Conditions
- Neuropathy;Peripheral
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Collaborators
- Foundation for Anesthesia Education and Research
- Study start
- 2 Nov 2023 (actual)
- Primary completion
- 1 Jun 2028 (estimated)
- Study completion
- 1 Jun 2028 (estimated)
- First posted
- 7 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To learn if a process called neuromodulation can help to improve pain due to CIP
Detailed description
Inclusion Criteria:
- Ability to understand and the willingness to sign a written informed consent document
- Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds
- Patients seen at Pain Management Center at MD Anderson Cancer Center
- Patient ages greater or equal to 18 years but less than or equal to 85 years
Exclusion Criteria:
- Patients with cognitive dysfunction
- Patient with recent history (<6 months) of drug or alcohol abuse
- Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection
- Patients with painful diabetic peripheral neuropathy or preexisting peripheral neuropathy
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Treatment Group | Experimental | Device: Abbott® DRG / Abbott®/Medtronic® SCSGroup 1 will receive neuromodulation. |
| Control Group | Experimental | Other: Control GroupGroup 2 will not receive neuromodulation. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Ability to understand and the willingness to sign a written informed consent document
- Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds
- Patients seen at Pain Management Center at MD Anderson Cancer Center
- Patient ages greater or equal to 18 years but less than or equal to 85 years
Key exclusion criteria (4 listed)
- Patients with cognitive dysfunction
- Patient with recent history (<6 months) of drug or alcohol abuse
- Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection
- Patients with painful diabetic peripheral neuropathy or preexisting peripheral neuropathy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Abbott® DRG / Abbott®/Medtronic® SCSParticipants will receive 1 of 2 neuromodulation procedures based on if participants are expected to have an MRI in the near future. | Device | Treatment Group |
| Control GroupParticipants will not receive any intervention | Other | Control Group |
Primary outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Time frame: through study completion; an average of 1 year.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2026.
- M D Anderson Cancer CenterLink provided by the sponsor.
Related trials for Neuropathy;Peripheral
RecruitingObservational study
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others
Charcot Marie Tooth Disease
RecruitingPhase 3
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Guillain-Barre Syndrome
RecruitingObservational study
Study of Inherited Neurological Disorders
Motor Neuron Disease, Muscular Disease
Not yet recruiting
Selective Nerve Root Block Versus Sham to Reduce Surgery for Lumbar Disc Herniation
Lumbar Disc Herniation, Lumbar Radiculopathy
Recruiting
Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy
Metastatic Bladder Cancer, Peripheral Neuropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Saba Javed, M D principal investigator
M.D. Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Abbott® DRG / Abbott®/Medtronic® SCS in people with Neuropathy;Peripheral, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Saba Javed, M D ((713) 792-9530, sjaved@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 (time frame: through study completion; an average of 1 year.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026.